Abstract
The ability to deliver or transduce proteins into cells allows for the manipulation of cell biology in culture, preclinical models, and potentially human disease. Fusion proteins containing the TAT peptide transduction domain (PTD), also known as cell-penetrating peptide (CPP), allow for delivery of a wide variety of proteins, including enzymes, transcription factors, tumor suppressor proteins, and many more. TAT-fusion proteins are generated cloning in-frame into the pTAT-HA plasmid, then transformed into E. coli for expression, and purified by the 6-His affinity tag over Ni-NTA column, followed by a final IEX FPLC purification step.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frankel AD, Pabo CO (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189–1193
Vives E, Brodin P, Lebleu B (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010–16017
Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310–315
Derossi D, Joliot AH, Chassaings G, Prochiantz A (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444–10450
Elloit G, O’Hare P (1997) Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223–233
Pooga M, Hällbrink M, Zorko M, Langel U (1998) Cell penetration by transportan. FASEB J 12(1):67–77. https://doi.org/10.1096/fasebj.12.1.67
Eguchi A, Meade BR, Chang YC, Fredrickson CT, Willert K, Puri N, Dowdy SF (2009) Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27:567–571
Kolosenko I, Edsbäcker E, Björklund AC, Hamil AS, Goroshchuk O, Grandér D, Dowdy SF, Palm-Apergi C (2017) RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-ALL patients. J Control Release 261:199–206
Goroshchuk O, Vidarsdottir L, Björklund AC, Hamil AS, Kolosenko I, Dowdy SF, Palm-Apergi C (2020) Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. Sci Rep 10(1):2688
Kolosenko I, Goroshchuk O, Vidarsdottir L, Björklund AC, Dowdy SF, Palm-Apergi C (2021) RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. FASEB J 35(5):e21476
Palm-Apergi C, Lorents A, Padari K, Pooga M, Hällbrink M (2009) The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J 23(1):214–223
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Palm-Apergi, C., Dowdy, S.F. (2022). Protein Delivery by PTDs/CPPs. In: Langel, Ü. (eds) Cell Penetrating Peptides. Methods in Molecular Biology, vol 2383. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1752-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1752-6_17
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1751-9
Online ISBN: 978-1-0716-1752-6
eBook Packages: Springer Protocols